China has introduced new implementing regulations of the drug administration law, set to take effect in 2026. The regulations may have implications for the life sciences industry, particularly with regards to supply chain security and compliance. The impact of these regulations on foreign companies and the potential for cross-border data risks are being assessed, although the specifics and potential consequences are not yet clear.